Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oh, C'mon... Significant dilution to these guys is doing dumps like this 5 days a week. They didn't dilute Monday or Tuesday, so this may just be a 3 day a week dilution (which apparently is not significant to them).
New CEO.. He's bringing all kinds of promises, will dilute and reverse it to death, then pass the reins on to another local who will do the same! Tom's bringing wealth to North Country in his own little wicked way
Didn't the 3 million shares get rescinded? Isn't that why trading was halted recently?
Shares potentially subject to rescission rights (3,307,830 shares issued and outstanding) $ 2,202,421
Stockholders' equity:
Common stock — $.0001 par value; 75,000,000 shares authorized; 13,824,207 issued and outstanding as of December 31, 2010 and 12,989,207 issued and outstanding as of March 31, 2010
Eh, my apologies... I see now!
Following the issuance of the shares in the preceding transactions, as of December 31, 2010, 17,132,037 shares of common stock are outstanding along with warrants to purchase an aggregate of 12,972,532 shares of common stock which are outstanding and UPOs to purchase an aggregate of 500,000 UPO Units.
At the end of 2010 13 million shares OS..
Common stock — $.0001 par value; 75,000,000 shares authorized; 13,824,207 issued and outstanding as of December 31, 2010 and 12,989,207 issued and outstanding as of March 31, 2010
Where do you have the belief of 29 million? We haven't even had that much volume to dump close to that! Just relax and wait for a nice heavy volume day as a lot of the shares were purchased by those at higher levels than this so will hold out for profit. We will take off!
By all means buy more. If we can get 4.95 billion shares in your hands, the pps may go up a little (right before the rs)
That PR did not state NO DILUTION or UNDER THIS AMOUNT OF DILUTION
That PR also stated they did are NOT PLANNING a RS. Of course Scumzafava stated "I do not consider a RS to be used as a tool to combat dilution" or something like that. But, even though he said it, he's reversed his 3 stocks about 10 times now!
I guess what I am getting at is that PR gave NOTHING SOLID and anything that was written there could be "due to unforseen circumstances" or "This amount of dilution didn't seem significant to us".
Good luck with your purchase, of course until you're calling the SEC again next week!
Message in reply to:
This stock will be worth $1 come sept. sit tight, HCKI will work its way up.
I had over $4k of SEVA stock and it isn't even worth a dollar now... Are you just waiting for a few reverse splits before you try to dump? Don't forget to average down!
I had nothing left when it went "PINK" as there were 3 reverse splits before that...
EXACTLY... GREAT POST
Also, in reply to your comment here - this line in particular..
Keeping that in mind when you buy a "PINK"! Driving through a bad section of town you do not expect to get robbed, but when you buy a "PINK" expect to get robbed, unless your lucky!
So you believe if you buy a pink stock, you it should automatically be ok for the CEO to lie, cheat, fool you to steal your money?
DID YOU NOT READ? When I bought into this CEO's Co, it was NOT PINK. IT was a fully reporting OTCBB stock - The CEO took it PINK
LOL... They are waiting to give the dividend shares out to HCKI first, make sure there are alot of "average downers" before they start dumping on it
Hmmm, I wonder about something... IF the FDIC proves wrongdoing on their part, do we have the right to go back and sue them, their insurance company, the debtors?
You think every pink CEO should be allowed to steal from shareholders, just because he's a PINKIE CEO? When I first got into SEVA it was a fully reporting OTCBB stock! I don't think any CEO should be allowed to do what Tom has, regardless if pinks, OTC, AMEX, or whatnot.
If you drive through a bad section of town, do you think it's legal for someone to rob you, just because you shouldn't have been in that section of town anyway?
Last 0.0002 Bid 0.0001 Ask 0.0002
High 0.0003 Low 0.0001
Volume
17,270,000
I'd say this is a pretty good indication that there will be NO DIVI today... Of course, there will probable be a PR about how they are having trouble with paperwork or something, but that it should happen 2 weeks from now.
Then, of course, Maury will want to back out of the deal because he found there is more debt in the shell or something and we'll be back with TS and a diluted pig and a Reverse Split...
Oh, and Tom will blame all this dilution on trying to get the shell over to Maury as it's not Tom's fault of course
If they do like they did in the case of Wamu, they seized tons of subs/assets regardless of whether they were owned by the banking unit or the holding company.
Of course trying to find out what assets are here may be a little easier as they aren't being ran by attorneys who want to kill equity!
Message in reply to:
The authorities could easily send them to prison for fraud and deceits. This is a dizzing maze of transactions and asset/debt shuffling but with motivation.
TS has been moving assets in/out of shells for 3-4 years now and there were numerous complaints. What makes you think the SEC or anyone else would finally do something about this one? They need to turn off the pr0n and get to work catching crooks
In the last financial filings available, HCKI showed $23 million in debt. This is the latest information available on the amount of debt outstanding.
They did state they wiped $10 million in debt off the books. To me that should show there is still $13 million in debt as that other $13 million was never "POOFED" away with a pen stroke.
This is NOT a clean shell and probably never could be with TS involved
so another words someone threatened you will telling the truth, that you know there is a scam going on but since that is not "public information" you're at risk of being sued?
Message in reply to:
We need everyone to buy and hold until this hits .0015 pps. This stock seems to move up or down easily for a triple zero sub penny stock. Load up on more shares at this low price. If everyone buys & holds their shares until major news comes out this will explode.
This could only come from someone with a sell order at .0013, what's your sell set at?
Message in reply to:
Not if you are persistent and contact the SEC and continue to ask them to go after these guys. They will shut this scam down and jail time for Tom & Maury.
You don't think this was done for 3 years straight at SEVA? While the CEO diluted it to death, PR's "I expect dilution to subside shortly" while signing 7 different CD's? This CEO been ripping off the shareholder for quite a while now and the SEC does nothing! About time for them to shut down the PORN and get to work!
Which shell owner are you speaking of? And how do you figure he's involved in 8 different pump & dumps?
Latest updates
3/15/2011 March 14, 2011, Biodel Inc. Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins
Biodel Inc. announced that it has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates. The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed meal time insulin analogs while maintaining an injection site tolerability profile comparable to currently marketed insulins. Biodel plans to test these formulations in a Phase 1 clinical trial of approximately 18 patients with Type 1 diabetes. This study is designed as a double blinded, three-period cross over trial in which patients will receive one subcutaneous injection of BIOD-105, BIOD-107 and Humalog(R) each on separate occasions. This study, expected to be completed in the third calendar quarter of 2011, will evaluate pharmacokinetic, pharmacodynamic and tolerability profiles of the two experimental insulins relative to that of Humalog(R). In parallel with this subcutaneous injection study, Biodel plans to utilize a similar design to conduct a clinical pump study this year. If this Phase 1 study is successful, Biodel now anticipates initiating a Phase 2 study in patients with Type 1 diabetes in the fourth calendar quarter of 2011. The Phase 2 study is intended to follow the same overall design that would be implemented in Phase 3 studies, which would include two separate pivotal trials-- one in patients with Type 1 diabetes, and the other in patients with Type 2 diabetes. Biodel recently received initial guidance from the U.S. Food and Drug Administration (FDA) on the design of two pivotal Phase 3 clinical trials. Based on this guidance, Biodel plans to design the Phase 2 and 3 studies as randomized parallel group studies using Humalog(R) as a comparator in which active dose titration will occur in the first two months after randomization followed by three months of relatively stable dosing. In these studies, Biodel plans to evaluate efficacy using HbA1c as well as measures of postprandial glucose profiles. If the results of the Phase 2 testing are successful, the company plans to launch Phase 3 pivotal studies required for approval in 2012 rather than its previous guidance of 2013.
2/4/2011 February 3, 2011, Biodel Inc. Reports Unaudited Earnings Results for the First Quarter Ended December 31, 2010
Biodel Inc. reported unaudited earnings results for the first quarter ended December 31, 2010. For the quarter, the company reported net loss of $5.3 million, or $0.20 per share, compared to a net loss of $11.1 million, or $0.47 per share, for the same period in the prior year.
2/1/2011 09064M10 9012155423~12/15/10~MMC~December 14, 2010, Biodel Announces Retirement of Solomon Steiner as Chief Scientific Officer~Biodel Inc. announced the retirement of Dr. Solomon Steiner as the company's Chief Scientific Officer. Steiner is a co-founder of Biodel and will remain a member of the company's board of directors. He served as Biodel's chairman, president and chief executive officer from its founding in December 2003 until March 2010 when Errol De Souza was named the company's president and chief executive officer and Charles Sanders was named board chairman.
12/15/2010 December 14, 2010, Biodel Announces Retirement of Solomon Steiner as Chief Scientific Officer Biodel Inc. announced the retirement of Dr. Solomon Steiner as the company's Chief Scientific Officer. Steiner is a co-founder of Biodel and will remain a member of the company's board of directors. He served as Biodel's chairman, president and chief executive officer from its founding in December 2003 until March 2010 when Errol De Souza was named the company's president and chief executive officer and Charles Sanders was named board chairman.
12/10/2010 December 9, 2010, Biodel Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2010
Biodel Inc. reported earnings results for the fourth quarter and full year ended September 30, 2010. For the quarter, the company reported a net loss of $8.1 million, or $0.31 per share, compared to a net loss of $10.5 million, or $0.44 per share, for the quarter ended September 30, 2009. For the full year ended September 30, 2010, operating loss before tax provision (benefit) was $38,394,000 against $42,933,000 a year ago. Net loss applicable to common stockholders was $38.3 million, or $1.58 per basic and diluted share, compared to $43.3 million, or $1.82 per basic and diluted share, for the fiscal year ended September 30, 2009.
12/7/2010 09064M10
9011025250~11/02/10~CON~November 1, 2010, FDA Issues Complete Response Letter to Biodel Inc. Regarding New Drug Application for Linjeta~Biodel Inc. announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) requesting additional information regarding the company's new drug application (NDA) for Linjeta(TM) (human insulin \rDNA origin\) injection 100IU/mL for the treatment of type 1 and type 2 diabetes mellitus to improve glycemic control. The CRL stated that the FDA's review cycle is complete and that the application cannot be approved in its present form. Biodel plans to contact the FDA within the coming weeks to request a meeting to discuss the company's next steps and requirements for approval of Linjeta(TM). The CRL included comments related to clinical trials, statistical analysis and chemistry, manufacturing and controls. With regard to efficacy, the FDA stated that, in the type 1 trial analysis, excluding data from India was post-hoc and therefore not sufficient for establishing conclusive evidence of efficacy. In the type 2 trial analysis, the FDA acknowledged that non-inferiority was established in the completer population but stated that non-inferiority was not established in the intent-to-treat population because the agency did not consider a post-hoc modification of the statistical model as establishing conclusive evidence of efficacy. With regard to safety, the FDA commented that unequivocal non-inferiority needs to be achieved in order to compare the risk of hypoglycemia. The FDA requested that the company conduct two new phase 3 clinical trials using the commercial formulation, one in patients with type 1 diabetes and the other in patients with type 2 diabetes, to establish efficacy and safety as related to hypoglycemia and toleration. The FDA also requested additional data related to stability and manufacturing. In addition, the FDA identified resolution of manufacturing issues related to recent site inspections at Hyaluron Inc. and Wockhardt Ltd. as a requisite for approval.
So another words...
Buying a million shares at $300 and receive 15-20% gain by the dividend. If they dilute this to the .0002's then you're talking about a $100 loss immediately, so even if the other stocks didn't drop by the time your shares are sellable/received (stock will probably be restricted) you're still talking about a loss. There are plenty of plays out there with better upside than dealing with a known dilution machine who's already taken thousands for their cash
Dividend in 4 days... And yet the pps is still going down and volume is pathetic! Does that not tell you something?
I believe Tom Scozzafava used to talk about "FRANCHISING" with the pizza joint he used to own (where is that asset now?)
Of course it takes cash to franchise... How do you think that's going to happen with owing tons of money to CD's, CD's to ex-owner, CD's to ex-owner's wife? A clean, low OS shell possibly, but a diluted pig already with a past like this one? LOL
So Maury Peters says he is no way any longer affiliated with Tom Scozzafava, yet... The title to that "HCKI to Dividend Shares of Affiliated Companies to it's shareholders?"
Are there some people out there that can't read between the lines and see that Scozzafava still the beneficiary of mucho shareholder cash?
NEWS... Hold tight!
Biodel Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins: Initiate Phase 2 in 2011; Phase 3 Pivotal Trials in 20126:59 am ET 03/14/2011 - PR NewswireDANBURY, Conn., Mar. 14, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) announced today that it has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates. The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed meal time insulin analogs while maintaining an injection site tolerability profile comparable to currently marketed insulins. Biodel plans to test these formulations in a Phase 1 clinical trial of approximately 18 patients with Type 1 diabetes. This study is designed as a double blinded, three-period cross over trial in which patients will receive one subcutaneous injection of BIOD-105, BIOD-107 and Humalog® each on separate occasions. This study, expected to be completed in the third calendar quarter of 2011, will evaluate pharmacokinetic, pharmacodynamic and tolerability profiles of the two experimental insulins relative to that of Humalog®. In parallel with this subcutaneous injection study, Biodel plans to utilize a similar design to conduct a clinical pump study this year.
If this Phase 1 study is successful, Biodel now anticipates initiating a Phase 2 study in patients with Type 1 diabetes in the fourth calendar quarter of 2011. The Phase 2 study is intended to follow the same overall design that would be implemented in Phase 3 studies, which would include two separate pivotal trials-- one in patients with Type 1 diabetes, and the other in patients with Type 2 diabetes. Biodel recently received initial guidance from the U.S. Food and Drug Administration (FDA) on the design of two pivotal Phase 3 clinical trials. Based on this guidance, Biodel plans to design the Phase 2 and 3 studies as randomized parallel group studies using Humalog® as a comparator in which active dose titration will occur in the first two months after randomization followed by three months of relatively stable dosing. In these studies, Biodel plans to evaluate efficacy using HbA1c as well as measures of postprandial glucose profiles. If the results of the Phase 2 testing are successful, the company plans to launch Phase 3 pivotal studies required for approval in 2012 rather than its previous guidance of 2013.
"We look forward to obtaining initial clinical data for BIOD-105 and BIOD-107," said Dr. Alan Krasner, Chief Medical Officer of Biodel. "Based on pharmacokinetic data obtained in the diabetic swine model, these formulations appear to be very rapidly absorbed, similar to rates of absorption seen with the previously studied Linjeta™ formulations. Based on last year's clinical data from related formulations BIOD-102 and BIOD-103, we anticipate improved injection site tolerability with BIOD-105 and BIOD-107. We were very pleased with our end of review meeting with the FDA in which they confirmed study details including the use of Humalog® as a comparator in future clinical trials. The FDA also confirmed that data from the development program for the new formulations would be classified as a Class 2 resubmission with a 6 month review time."
"We have identified two new formulations with commercial target product profiles that appear to be superior to any of our previous ultra-rapid-acting human insulin drug candidates," said Dr. Errol De Souza, president and CEO of Biodel. "By achieving our candidate selection milestone and receiving constructive feedback from the FDA during our end of review meeting, we have accelerated the clinical development program of these formulations and plan to initiate Phase 1 clinical testing this month and could initiate Phase 3 testing before the end of 2012."
Biodel now expects to complete the Phase 1 study and launch Phase 2 testing in the third and fourth calendar quarters of 2011, respectively.
Dr. De Souza will address these accelerated time lines and other updates in a presentation at the Roth 23rd Annual OC Growth Stock ConferenceWednesday, March 16th at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time). Interested parties may access the presentation in the investor relations section of Biodel's website at www.biodel.com which will link to a live webcast to be archived for 14 days.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. For further information regarding Biodel, please visit the company's website at www.biodel.com.
Safe-Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements about future activities related to the clinical development plans for the company's drug candidates, including the potential timing, design and outcomes of clinical trials; and the company's ability to develop and commercialize product candidates. Forward-looking statements represent our management's judgment regarding future events. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to respond to the complete response letter regarding our new drug application for Linjeta™ in a timely manner and the possibility that information we provide in response to the letter may not be accepted by the FDA; our ability to secure FDA approval for Linjeta™ and our other product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel™ technology; the progress or success of our research, development and clinical programs and the initiation and completion of our clinical trials; the possibility that patients taking Linjeta™ may experience more injection site discomfort than they experience with competing products; unexpected data that may result from our clinical trials and our research and development activities; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of future performance; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of those collaborations after consummation, if consummated; the rate and degree of market acceptance and clinical utility of our products; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our most recent annual report on Form 10-Q for the quarter ended December 31, 2010. The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.
Let me guess? 1931?
Short Interest (Shares Short) 4,228,300
Days To Cover (Short Interest Ratio) 6.1
Short Interest - Prior 4,577,000
Short % Increase / Decrease -7.62
Shorts are covering, time to take it up a notch toward that 52wk high of 6.25
I've been through Scozzafava's stocks before... Yes, I considered a pitchfork in my hand at one time! :)
Is this what the news release will say?
"Hundreds of HCKI shareholders lose everything in scam. According to press releases HCKI was going to cancel 1.8 billion common shares leaving just under 1.4 billion remaining, less than half which is supposed to make the price go up. As news reports have found there has been billions of new shares hitting the market during this time.
The CEO Maury Peters, and the ex-CEO Tom Scozzafava are hiding from shareholders with pitchforks who are roaming the streets of Watertown, NY looking for the pair. The National Guard has been called in to prevent the rioters from mass destruction as the SEC & Attorney General are said to be looking into allegations of a scam.
Many of these shareholders were innocent bystanders in what's known as a pump and dump on penny stocks. A pump and dump occurs when some are paid by the companies and/or form groups to buy into the stock low and bring on other investors only to dump their shares at a profit at that time while those new investors lose it all."
Steady climb from here
Shares Outstanding5: 26.43M
Float: 21.62M
% Held by Insiders6: 31.59%
% Held by Institutions6: 28.80%
Shares Short (as of Feb 15, 2011)3: 4.58M
Short Ratio (as of Feb 15, 2011)3: 5.10
Short % of Float (as of Feb 15, 2011)3: 20.70%
Shares Short (prior month)3: 4.37M
60% Insider/Institutional ownership and only 26 MIL OS.
So this only leaves about 10 million shares flying around for us little guys and with over 4 and a half million shares yesterday being bought up there can't be too many left!
Recent news from Roth Capital
http://biotuesdays.com/2011/03/08/roth-starts-biodel-at-buy/
Roth starts Biodel at buy
March 8, 2011 by leonardzehr · Leave a Comment
Roth Capital Partners has initiated coverage of Biodel (NASDAQ:BIOD) with a “buy” rating and 12-month price target of $4, saying the shares “appear undervalued” and “there may be meaningful upside” to the price target. The stock closed at $1.95 on Monday.
Biodel is developing a second generation version of Linjeta, a fast-acting formulation of insulin, after the FDA rejected Linjeta in 2010. “We believe that G2 Linjeta is an approvable drug,” writes analyst Andrew Vaino, adding that the “Phase 3 data for of Linjeta were not all bad…which gives us confidence that the G2 version is likely to be approved.”
G2 Linjeta sales could exceed $2 billion a year, he predicts and notes that his price target does not take potential European sales into account, and models nothing for upfront milestones from a potential partnership.
Biodel’s technology is simple but clever, he points out. Fast-acting insulins are all chemically modified proteins, whereas Linjeta is not. Insulin exists as a hexamer, or a grouping of six individual peptides, held together around a zinc ion. Biodel has patented a technique for separating the hexamer into monomers. By applying the insulin monomer, which is what Biodel does, absorption is accelerated and glucose can be better controlled
How are you able to get the restricted when I even spoke to the manager and she said need to contact co?
Ride's not over with yet...
Ok... So I took it upon myself to call the TA today since you're calling me out.
3,209,256,783 is total OS given by Marilyn 469-633-0101. She stated that is the most recent information she has, but there could be shares going through a broker that she would not know about until the company or broker notifies her. The TA WILL NOT give out float/restricted as Marilyn said I needed to call the company for that information and gave me a phone number for Maury Peters. The number I was given WAS NOT Maury Peter's phone number as the guy sounded fairly agitated when I asked for Maury (apparently I'm not the only one calling this number for Maury) but it does show up a Watertown NY number in my phone's recent calls.
I am not sure how the other guy was able to get float/restricted by emailing TA when she stated it is not and has not been available through them, he must have some good connections... Of course the Email coming from Scozzafava could/should be BS because he's not even in charge of the shell
OK, so what do we really know? We know the current OS as far as Marilyn has information of to be 3.2 BILLION. We do not know the restricted/float and/or if the other 1.8 billion that is supposedly getting cancelled is of the 3.2 BILLION as Marilyn said she had heard something about a share cancellation, but doesn't have any further information other than what she's heard.
The number I was given for Maury Peters is 315-771-3034 and had even read it back to Marilyn while on the phone so I do not think I had the phone number wrong.
Yes, share cancellation of the 1.8 billion shares they currently hold as Tom is getting a CD for 3.5 billion shares to dump at will
They stated they were cancelling 1.8 billion common shares, they said nothing about issuing other shares. If you don't know Tom, he definitely knows enough to keep it clean, even though unethical.
Tom expected dilution to subside shortly in SEVA as he was signing his name to 9 different CD's, knowing those shares would be dumped. The dumpage went from being able to handle to an all out dumpfest.
Whatcha mean "Man enough to call"? Are you trying to say a penny stock CEO won't tell you just enough to keep you interested, but not enough to make you sell?
Doesn't matter calling CEO's... The guys doing this type of thing are crooks, then pass it off to another to rinse/repeat